-

Leesa Lertsumitkul – Brain Cancer Centre

26/02/2025 12:00 pm - 26/02/2025 1:00 pm
Location
Davis Auditorium

WEHI Wednesday Seminar hosted by Professor Misty Jenkins
 

Leesa Lertsumitkul
PhD Student – Jenkins Laboratory, Brain Cancer Centre – Personalised Oncology division, WEHI
(this is a PhD Completion seminar)
 

Developing novel targeted CAR T cell therapies for high-grade gliomas 
 

Davis Auditorium
Join via SLIDO enter code #WEHIWednesday

Including Q&A session
  

High-grade gliomas, such as glioblastoma (GBM) and diffuse midline gliomas (DMG), are relatively rare brain cancers but are highly aggressive and remain incurable. Current treatment options of surgery, chemotherapy and radiotherapy have not changed in over 20 years and survival rates remain abysmal – a median survival rate of 1-2 years for GBM and < 1 year for DMG. Next-generation cellular therapies including chimeric antigen receptor (CAR) T cell therapies have been transformative in treating haematological malignancies. Now the field is looking to translate this success into solid tumours, particularly brain cancer. Optimal selection of target antigens remains one of the key challenges for CAR T cell therapies treating solid tumours due to their heterogenous antigen expression and the risk of causing on-target off-tumour toxicities.

To establish a clinically relevant novel target discovery platform, our group have employed cell surface proteomic analysis of high-grade glioma patient samples to map the most abundant cell surface proteins. We identified a key protein, Ephrin type-A receptor 3 (EphA3), as prevalently expressed within this patient cohort. My PhD has focused on developing a novel EphA3-targeted CAR T cell therapy and validating its efficacy in preclinical models of GBM and DMG. Using orthotopic xenograft mouse models, I have demonstrated that this novel CAR T cell therapy exhibits a robust anti-tumour effect, resulting in complete and sustained tumour clearances. I also discovered that these CAR T cells formed a functional memory T cell population that was protective upon a second tumour challenge. My findings provide compelling preclinical evidence supporting the efficacy of EphA3-targeted CAR T cells for the treatment of high-grade gliomas, demonstrating promising potential for clinical translation. My seminar will outline the current landscape of CAR T cell therapies in brain cancer research and how my work contributes to this evolving field.

 

All welcome!

Support us

Together we can create a brighter future

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Sign up to our quarterly newsletter Illuminate

Find out about recent discoveries, community supporters and more.

Illuminate Summer 2024
View the current issue